<DOC>
	<DOCNO>NCT00536835</DOCNO>
	<brief_summary>This first time human study do determine maximum tolerate dose initial pharmacokinetic parameter GSK461364 , give IV , adult subject solid tumor Non-Hodgkins lymphoma .</brief_summary>
	<brief_title>Study Assess Pharmacokinetics Pharmacodynamics GSK461364 Subjects With Non-Hodgkins Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>Confirmed diagnosis advance solid tumor NonHodgkins Lymphoma ( exclude HIVassociated lymphoma ) relapse refractory standard therapy At least 18 year age Female nonchildbearing potential negative pregnancy test use approve contraception Male female partner childbearing potential must vasectomy use approved contraception Lab value within range describe protocol Paraffinembedded archival tumor tissue available testing Signed write informed consent Undergone major surgery receive anticancer therapy History hemolytic anemia Clinical lab test range describe protocol Females pregnant lactate Significant heart problem Serious unstable preexist medical psychiatric condition Are able comply study protocol Use prohibit medication Have low blood pressure Evidence symptomatic untreated central nervous system involvement require corticosteroid antiepileptic med</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Non-Hodgkins Lymphoma</keyword>
	<keyword>Cancer</keyword>
	<keyword>First time human</keyword>
	<keyword>PLK1 inhibitor</keyword>
	<keyword>Advanced Solid Tumor</keyword>
	<keyword>GSK461364</keyword>
</DOC>